https://www.idival.org/wp-content/uploads/2022/05/cab-presentacion.jpg

Researchers from the Valdecilla environment participate in an international genetic study that identifies genetic variations associated with severe COVID-19

1 de June de 2023

The study, published in the prestigious scientific journal, opens the door to the development of new treatments Researchers from the Marqués de Valdecilla University Hospital (HUMV) and the Marqués de Valdecilla Research Institute (IDIVAL) are participating in an international genetic study published in the journal Nature that reveals new therapeutic targets that could facilitate the […]

Read more →

The study, with the participation of IDIVAL, could help in the future diagnosis and treatment of the disease

31 de May de 2023

Spinocerebellar ataxia type 15 (SCA15), characterized by alterations in the strength, speed and dexterity of movements, is the disease on which the genetic study that could help in its diagnosis and treatment in the future has focused. Neurologists and geneticists from different centers have participated in the research, including the researcher José Berciano from the […]

Read more →

IDIVAL leads a multicenter study on axial spondyloarthritis disease

8 de May de 2023

The results of the latest study will allow progress to be made in the design of specific strategies for the management of cardiovascular risk according to sex. The ‘Immunopathology’ group of the Marqués de Valdecilla Health Research Institute (IDIVAL) coordinates a multicenter study with a dozen Spanish hospitals to investigate cardiovascular risk in patients with […]

Read more →

Dr. Francisco Sánchez Madrid, member of IDIVAL’s external board, receives the Robert Koch research award

5 de May de 2023

Francisco Sánchez Madrid, member of IDIVAL’s External Council and Head of the Immunology Service of the Hospital Universitario de La Princesa has received the Robert Koch Award 2023. The immunologist and professor at Harvard University in Boston, Timothy Springer, has also been awarded this prize for their important joint research in Immunology. Both were pioneers […]

Read more →

United for a Challenge’ collaborates one more year with IDIVAL’s Alzheimer’s research

4 de May de 2023

These donations are destined to study Alzheimer’s markers to detect people at high risk of suffering from this disease in the future. IDIVAL has received one more year the visit of Oscar Negrete and Fernando Cerro from the association ‘Unidos por un Reto’ to make a donation of 800€ that will be destined to Alzheimer’s […]

Read more →

Blood test could detect and monitor rare neurodegenerative disease SCA3

3 de May de 2023

The results open the possibility of using 5 genes identified as markers that correlate with the severity of the disease in the brain. The `Neurodegenerative Diseases´ group of the Marqués de Valdecilla Health Research Institute (IDIVAL) led by Dr. Jon Infante Ceberio has participated in a european multicenter study with the aim of identifying genes […]

Read more →

New study reveals genetic causes of patients with reduced phosphorus levels

20 de April de 2023

The research team from IDIVAL, HUMV and Sierrallana Hospital indicates that the results could help to prescribe the appropriate treatment and prevent complications. Identifying the causes of the decrease in the concentration of phosphorus in the blood was the main objective of the study carried out by the research team belonging to the Marqués de […]

Read more →

IDIVAL researchers explain the origin of COVID-19 headache and diarrhoea, two of the most frequent symptoms of this infection

10 de April de 2023

This study sheds light on the processes that cause these ailments and possible future treatments. A research team from the Marqués de Valdecilla Health Research Institute (IDIVAL) and the Marqués de Valdecilla University Hospital (HUMV) has demonstrated the involvement of a molecule, a peptide known as CGRP, in COVID-19 infection, specifically in headache and diarrhoea, […]

Read more →

The Nanomedicine Group of IDIVAL designs a new gene transfer system based on nanotechnology

5 de April de 2023

The biocompatibility, stability and reproducibility of this novel method allows its industrial production for uses such as personalized therapy.  The Nanomedicine Group of the Marqués de Valdecilla Health Research Institute (IDIVAL) has designed and optimized a novel method based on nanoparticles capable of encapsulating, storing and transferring genetic material into cells. The procedure is easily […]

Read more →

Valdecilla-IDIVAL participates in a study that discovers blood biomarkers that could predict the onset of symptoms in a genetic Parkinson’s subtype

6 de March de 2023

Researchers from the IDIVAL neurodegenerative diseases group and the Movement Disorders Unit of the Marqués de Valdecilla University Hospital (HUMV) have participated in a recent study, promoted by the Clínic Barcelona-IDIBAPS, which has detected alterations in the expression profile of four microRNAs, which could make it possible to detect the onset of genetic Parkinson’s disease […]

Read more →